Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Nefazodone | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Nefazodone | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | | Nefazodone | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Nefazodone | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Nefazodone | hsa00220 | Arginine biosynthesis | 3.02E-05 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Nefazodone | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Nefazodone | hsa00310 | Lysine degradation | 3.15E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Nefazodone | hsa00500 | Starch and sucrose metabolism | 6.79E-08 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Nefazodone | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Nefazodone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Nefazodone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Nefazodone | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Nefazodone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 6.37E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Nefazodone | hsa00730 | Thiamine metabolism | 2.21E-07 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Nefazodone | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Nefazodone | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Nefazodone | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Nefazodone | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Nefazodone | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.92E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Nefazodone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Nefazodone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Nefazodone | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Nefazodone | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Nefazodone | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Nefazodone | hsa01230 | Biosynthesis of amino acids | 1.42E-04 | 5 | P51854, P60891, Q99707, P15104, P37837 | TKTL1, PRPS1, MTR, GLUL, TALDO1 | More | | Nefazodone | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Nefazodone | hsa02010 | ABC transporters | 1.66E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Nefazodone | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Nefazodone | hsa03013 | RNA transport | 3.08E-05 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3 | More | | Nefazodone | hsa03020 | RNA polymerase | 5.06E-03 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Nefazodone | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Nefazodone | hsa03040 | Spliceosome | 4.08E-05 | 12 | Q14562, O60508, P08579, P26368, Q13595, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Nefazodone | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Nefazodone | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Nefazodone | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Nefazodone | hsa04012 | ErbB signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | | Nefazodone | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Nefazodone | hsa04024 | cAMP signaling pathway | 4.80E-02 | 1 | Q13153 | PAK1 | More | | Nefazodone | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Nefazodone | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.70E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | Nefazodone | hsa04062 | Chemokine signaling pathway | 6.08E-06 | 15 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, GSK3B | More | | Nefazodone | hsa04064 | NF-kappa B signaling pathway | 7.87E-09 | 20 | P10415, Q13489, P25963, P51617, O00463, P14778, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.766 | P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | P06737 | PYGL | Glycogen phosphorylase, liver form | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.924 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.783 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.967 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q8WV28 | BLNK | B-cell linker protein | -0.706 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | P06737 | PYGL | Glycogen phosphorylase, liver form | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.822 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09341 | CXCL1 | Growth-regulated alpha protein | 0.74 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 |
| Nefazodone | hsa04071 | Sphingolipid signaling pathway | 2.41E-06 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Nefazodone | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Nefazodone | hsa04080 | Neuroactive ligand-receptor interaction | 1.08E-04 | 11 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550, P35318 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2, ADM | More | | Nefazodone | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Nefazodone | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Nefazodone | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Nefazodone | hsa04142 | Lysosome | 2.64E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Nefazodone | hsa04144 | Endocytosis | 1.24E-02 | 9 | Q13191, P11142, O75351, P62491, P25024, P43250, Q14161, P14784, Q9Y5X3 | CBLB, HSPA8, VPS4B, RAB11A, CXCR1, GRK6, GIT2, IL2RB, SNX5 | More | | Nefazodone | hsa04145 | Phagosome | 7.50E-03 | 10 | Q15080, P14598, Q13509, Q13488, Q99437, P05164, O60603, P35443, P13765, P25774 | NCF4, NCF1, TUBB3, TCIRG1, ATP6V0B, MPO, TLR2, THBS4, HLA-DOB, CTSS | More | | Nefazodone | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | | Nefazodone | hsa04210 | Apoptosis | 2.95E-04 | 14 | Q13315, P10415, Q13489, O76075, P25963, P01375, Q9NR28, O75460, P24522, Q16548, Q13077, O43521, P18848, Q14643 | ATM, BCL2, BIRC3, DFFB, NFKBIA, TNF, DIABLO, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, ATF4, ITPR1 | More | | Nefazodone | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Nefazodone | hsa04217 | Necroptosis | 3.89E-04 | 9 | P01375, P48023, Q14765, P15104, P05141, P01584, P0C0S5, Q99878, Q9H444 | TNF, FASLG, STAT4, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CHMP4B | More | | Nefazodone | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Nefazodone | hsa04340 | Hedgehog signaling pathway | 1.76E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Nefazodone | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Nefazodone | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | Nefazodone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Nefazodone | hsa04610 | Complement and coagulation cascades | 1.15E-08 | 1 | P0C0L4 | C4A | More | | Nefazodone | hsa04612 | Antigen processing and presentation | 2.51E-06 | 9 | P13765, P01730, Q14953, P26715, P26717, Q07444, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, CD8A, TNF | More | | Nefazodone | hsa04613 | Neutrophil extracellular trap formation | 2.56E-06 | 21 | P17252, O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Nefazodone | hsa04621 | NOD-like receptor signaling pathway | 3.34E-04 | 14 | Q16539, Q14643, P25963, Q13489, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P49913, P12838 | MAPK14, ITPR1, NFKBIA, BIRC3, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, CAMP, DEFA4 | More | | Nefazodone | hsa04625 | C-type lectin receptor signaling pathway | 8.18E-03 | 5 | Q9ULY5, Q13153, P20749, P01375, Q16539 | CLEC4E, PAK1, BCL3, TNF, MAPK14 | More | | Nefazodone | hsa04640 | Hematopoietic cell lineage | 1.03E-05 | 11 | P13612, P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | | Nefazodone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.01E-14 | 15 | P19174, P01375, P06239, O60880, P20963, P42338, Q13153, Q13241, P26718, O14931, O75015, P26717, Q07444, Q14953, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, PAK1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.78 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.767 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.726 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.829 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.726 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Nefazodone | hsa04657 | IL-17 signaling pathway | 1.15E-06 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Nefazodone | hsa04658 | Th1 and Th2 cell differentiation | 1.83E-15 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P42226, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, STAT6, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.734 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.812 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.736 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.849 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.705 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.855 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.884 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.73 |
| Nefazodone | hsa04659 | Th17 cell differentiation | 4.18E-12 | 16 | Q04759, Q16539, P19174, P01730, P06239, P42226, P14784, P13765, P14778, Q9UL17, P23771, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT6, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.734 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P06737 | PYGL | Glycogen phosphorylase, liver form | P42226 | STAT6 | Signal transducer and activator of transcription 6 | 0.852 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.738 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.705 | P06737 | PYGL | Glycogen phosphorylase, liver form | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.753 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.849 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.729 | P07948 | LYN | Tyrosine-protein kinase Lyn | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.782 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.812 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 |
| Nefazodone | hsa04660 | T cell receptor signaling pathway | 1.11E-11 | 19 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, Q13153, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, PAK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q04759 | PRKCQ | Protein kinase C theta type | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.734 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P08246 | ELA2 | Neutrophil elastase | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | -0.854 | P06737 | PYGL | Glycogen phosphorylase, liver form | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.724 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.737 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.8 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P08246 | ELA2 | Neutrophil elastase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.782 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.752 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.72 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P06737 | PYGL | Glycogen phosphorylase, liver form | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.815 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Nefazodone | hsa04662 | B cell receptor signaling pathway | 2.54E-04 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Nefazodone | hsa04664 | Fc epsilon RI signaling pathway | 2.20E-03 | 6 | P01375, Q16539, P42338, Q9UQC2, P07948, P09917 | TNF, MAPK14, PIK3CB, GAB2, LYN, ALOX5 | More | | Nefazodone | hsa04668 | TNF signaling pathway | 1.99E-05 | 12 | P01375, O00463, Q13489, Q16539, P25963, P18848, P19875, P01584, P20749, Q13077, P14780, P20333 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, ATF4, CXCL2, IL1B, BCL3, TRAF1, MMP9, TNFRSF1B | More | | Nefazodone | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Nefazodone | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Nefazodone | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Nefazodone | hsa04724 | Glutamatergic synapse | 3.88E-04 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | Nefazodone | hsa04725 | Cholinergic synapse | 4.10E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | | Nefazodone | hsa04727 | GABAergic synapse | 1.82E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Nefazodone | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Nefazodone | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Nefazodone | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Nefazodone | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Nefazodone | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Nefazodone | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Nefazodone | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Nefazodone | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Nefazodone | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Nefazodone | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Nefazodone | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 9 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679, P49407 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15, ARRB1 | More | | Nefazodone | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Nefazodone | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Nefazodone | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Nefazodone | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | | Nefazodone | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Nefazodone | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Nefazodone | hsa04964 | Proximal tubule bicarbonate reclamation | 2.17E-03 | 1 | P00918 | CA2 | More | | Nefazodone | hsa04966 | Collecting duct acid secretion | 9.41E-05 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Nefazodone | hsa04970 | Salivary secretion | 2.82E-03 | 5 | P07550, P22694, Q14643, P17252, P49913 | ADRB2, PRKACB, ITPR1, PRKCA, CAMP | More | | Nefazodone | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Nefazodone | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Nefazodone | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | Nefazodone | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Nefazodone | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Nefazodone | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | | Nefazodone | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Nefazodone | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.94E-04 | 13 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2 | More | | Nefazodone | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Nefazodone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Nefazodone | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Nefazodone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.35E-06 | 8 | Q16539, Q13153, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, PAK1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Nefazodone | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Nefazodone | hsa05132 | Salmonella infection | 2.98E-02 | 11 | P51617, P25963, P01375, Q9UJU2, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, Q13509 | IRAK1, NFKBIA, TNF, LEF1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, TUBB3 | More | | Nefazodone | hsa05133 | Pertussis | 3.47E-04 | 1 | P0C0L4 | C4A | More | | Nefazodone | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Nefazodone | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Nefazodone | hsa05140 | Leishmaniasis | 9.33E-04 | 10 | O75015, P14598, P13765, O60603, P25963, P01375, P49006, Q16539, P51617, Q15080 | FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Nefazodone | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Nefazodone | hsa05144 | Malaria | 1.12E-04 | 6 | P60033, P69905, P68871, P01375, P35443, P26718 | CD81, HBA2, HBB, TNF, THBS4, KLRK1 | More | | Nefazodone | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Nefazodone | hsa05146 | Amoebiasis | 1.52E-08 | 13 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Nefazodone | hsa05150 | Staphylococcus aureus infection | 5.34E-03 | 8 | P0C0L4, P21730, P21462, O75015, P13765, Q16581, P13646, P12838 | C4A, C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, KRT13, DEFA4 | More | | Nefazodone | hsa05152 | Tuberculosis | 9.13E-03 | 11 | Q13488, Q99437, P48382, O60603, P01375, P10415, P13765, P25774, P49913, Q9UDY8, P51617 | TCIRG1, ATP6V0B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CTSS, CAMP, MALT1, IRAK1 | More | | Nefazodone | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Nefazodone | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Nefazodone | hsa05163 | Human cytomegalovirus infection | 1.78E-04 | 10 | P01375, P63218, P50151, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Nefazodone | hsa05169 | Epstein-Barr virus infection | 1.44E-04 | 18 | P13765, P01106, Q13547, O00463, P16070, P10415, Q16539, P42338, P07948, Q13761, P24522, O75293, Q8WV28, P01375, O60603, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, CD44, BCL2, MAPK14, PIK3CB, LYN, RUNX3, GADD45A, GADD45B, BLNK, TNF, TLR2, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06737 | PYGL | Glycogen phosphorylase, liver form | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.845 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P06239 | LCK | Tyrosine-protein kinase Lck | P01106 | MYC | Myc proto-oncogene protein | 0.719 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Q13547 | HDAC1 | Histone deacetylase 1 | -0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13547 | HDAC1 | Histone deacetylase 1 | 0.811 | P06737 | PYGL | Glycogen phosphorylase, liver form | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.924 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P06737 | PYGL | Glycogen phosphorylase, liver form | P16070 | CD44 | CD44 antigen | 0.803 | P06737 | PYGL | Glycogen phosphorylase, liver form | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.766 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.863 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.735 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.708 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | P06737 | PYGL | Glycogen phosphorylase, liver form | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.822 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.768 | P06737 | PYGL | Glycogen phosphorylase, liver form | Q8WV28 | BLNK | B-cell linker protein | -0.706 | P06737 | PYGL | Glycogen phosphorylase, liver form | P01375 | TNF | Tumor necrosis factor | 0.759 | P06737 | PYGL | Glycogen phosphorylase, liver form | O60603 | TLR2 | Toll-like receptor 2 | 0.836 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06737 | PYGL | Glycogen phosphorylase, liver form | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.723 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P06737 | PYGL | Glycogen phosphorylase, liver form | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.728 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 |
| Nefazodone | hsa05170 | Human immunodeficiency virus 1 infection | 1.06E-03 | 13 | P01375, P17252, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P10415, Q13619, Q93034, Q9Y6Q5 | TNF, PRKCA, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, BCL2, CUL4A, CUL5, AP1M2 | More | | Nefazodone | hsa05202 | Transcriptional misregulation in cancer | 5.55E-07 | 18 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q16548, Q13489, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | Nefazodone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Nefazodone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Nefazodone | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Nefazodone | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | | Nefazodone | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Nefazodone | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Nefazodone | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Nefazodone | hsa05222 | Small cell lung cancer | 2.79E-02 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Nefazodone | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Nefazodone | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | Nefazodone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.10E-07 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Nefazodone | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Nefazodone | hsa05321 | Inflammatory bowel disease | 1.94E-06 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | Nefazodone | hsa05322 | Systemic lupus erythematosus | 1.11E-05 | 14 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, Q16778, O60814, P68431, P12814, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1, SSB | More | | Nefazodone | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Nefazodone | hsa05332 | Graft-versus-host disease | 2.84E-06 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Nefazodone | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Nefazodone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 6.71E-04 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Nefazodone | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Nefazodone | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Nefazodone | hsa05418 | Fluid shear stress and atherosclerosis | 1.79E-05 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |